Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commit Sales Contribute To 25% Gain In GSK Smoking Cessation Sales In Q4

This article was originally published in The Tan Sheet

Executive Summary

Sales of GlaxoSmithKline's Commit nicotine polacrilex lozenge helped drive the company's fourth quarter smoking cessation sales to $198 mil., up 25% at constant exchange rates compared with the year-ago period

You may also be interested in...



GSK Respiratory OTC Sales Up 13% In Q1

Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan

GSK Respiratory OTC Sales Up 13% In Q1

Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan

GSK Respiratory OTC Sales Up 13% In Q1

Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel